{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-175494","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.579641+00:00","generated_at":"2026-05-17T17:43:49.686614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025","bullets":["Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.","Cash, cash equivalents & investments $1.2B as of June 30, 2025; expected runway into 2029.","Paltusotine NDA PDUFA target action date September 25, 2025 for acromegaly; EMA review expected H1 2026.","Upcoming Phase 3 starts in H2 2025 for paltusotine in carcinoid syndrome and atumelnant in CAH (adult and pediatric).","2025 cash used in operations guided at $340-370M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-175494","json":"https://secwatch.observer/filing/0001193125-25-175494.json","markdown":"https://secwatch.observer/filing/0001193125-25-175494.md","text":"https://secwatch.observer/filing/0001193125-25-175494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312525175494/0001193125-25-175494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312525175494/crnx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:43:49.686614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}